{"entity":{"id":"nct02704858","kind":"trial","name":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","aka":[],"tldr":"A phase 1/2 trial of Perillyl alcohol in glioma & glioblastoma, run by Neonc Technologies, Inc., active and no longer recruiting.","summary":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma is a phase 1/2 interventional study registered as NCT02704858 by Neonc Technologies, Inc., with 49 participants enrolled, started 2017-08-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Perillyl alcohol.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02704858","url":"https://clinicaltrials.gov/study/NCT02704858"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["neonc-technologies"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02704858","phase":"1/2","setting":"An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation","sponsor":"Neonc Technologies, Inc.","enrolled":49,"outcomes":[]},"route":"/trials/nct02704858/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/"}]}}